Cardiol Therapeutics (CRDL) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free CRDL Stock Alerts $2.32 +0.14 (+6.42%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 10:53 PM | investorplace.comCRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024May 14 at 12:31 PM | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Cardiol Therapeutics in a research note on Tuesday.May 14 at 10:56 AM | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest UpdateCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) saw a large growth in short interest in April. As of April 30th, there was short interest totalling 328,100 shares, a growth of 19.2% from the April 15th total of 275,200 shares. Based on an average trading volume of 391,900 shares, the short-interest ratio is currently 0.8 days. Approximately 0.5% of the company's stock are sold short.May 14 at 9:38 AM | proactiveinvestors.comCardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditisApril 24, 2024 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Earn Q1 2024 Earnings of ($0.06) Per ShareCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Cardiol Therapeutics in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst V. Bernardino expects that theApril 22, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on Cardiol Therapeutics in a report on Monday. They issued a "buy" rating and a $9.00 price objective on the stock.April 2, 2024 | investorplace.comCRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023April 2, 2024 | proactiveinvestors.comCardiol Therapeutics surpasses enrollment goals, prepares for topline resultsMarch 28, 2024 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Post FY2024 Earnings of ($0.31) Per ShareCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at Leede Jones Gab boosted their FY2024 EPS estimates for Cardiol Therapeutics in a note issued to investors on Monday, March 25th. Leede Jones Gab analyst D. Loe now anticipates that the company will earn ($0.31) per share for theMarch 25, 2024 | marketbeat.comCardiol Therapeutics (CRDL) to Release Earnings on TuesdayCardiol Therapeutics (NASDAQ:CRDL) will be releasing earnings on Tuesday, March 26, Yahoo Finance reports.March 16, 2024 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Friday (CRDL-WT-A)March 13, 2024 | marketbeat.comShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Increases By 108.1%Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 29th, there was short interest totalling 361,100 shares, an increase of 108.1% from the February 14th total of 173,500 shares. Approximately 0.6% of the company's stock are sold short. Based on an average daily volume of 335,900 shares, the short-interest ratio is currently 1.1 days.February 22, 2024 | benzinga.comCardiol Therapeutics Stock (NASDAQ:CRDL), Short Interest ReportFebruary 21, 2024 | proactiveinvestors.comCardiol Therapeutics wraps up patient enrollment for Phase II open label studyFebruary 16, 2024 | proactiveinvestors.comCardiol CEO David Elsley unpacks FDA Orphan Drug Designation for CardiolFebruary 15, 2024 | proactiveinvestors.comCardiol Therapeutics receives orphan drug status for its lead drug...February 15, 2024 | theglobeandmail.comOrphan Drug Designation Sends Shares of this Dual-Listed Life Science Therapy Company SoaringFebruary 15, 2024 | msn.comCardiol stock rallies 28% on FDA orphan drug status for CardiolRxFebruary 15, 2024 | proactiveinvestors.comCardiol Therapeutics receives orphan drug status for its lead drug candidateJanuary 30, 2024 | marketbeat.comShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Drops By 9.0%Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 119,600 shares, a decrease of 9.0% from the December 31st total of 131,500 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average trading volume of 144,800 shares, the days-to-cover ratio is presently 0.8 days.January 9, 2024 | morningstar.comCardiol Therapeutics Inc Class A CRDLJanuary 9, 2024 | finance.yahoo.comCardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute MyocarditisDecember 18, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Tuesday (CRDL-WT-A)November 16, 2023 | finance.yahoo.comCardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesOctober 11, 2023 | finance.yahoo.comCardiol Therapeutics releases positive study results of subcutaneously administered cannabidiolOctober 10, 2023 | proactiveinvestors.comCardiol Therapeutics says study results show positive effects of subcutaneously administered cannabidiolOctober 10, 2023 | finance.yahoo.comCardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection FractionOctober 2, 2023 | benzinga.comCardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)September 27, 2023 | finance.yahoo.comHere's Why You May Invest in Cardiol Therapeutics (CRDL) StockSeptember 19, 2023 | finance.yahoo.comCardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute MyocarditisAugust 26, 2023 | finance.yahoo.comIs Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?August 9, 2023 | finance.yahoo.comCardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth ConferenceAugust 4, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc flat on Wednesday (CRDL)June 29, 2023 | finance.yahoo.comCardiol Therapeutics Reports Results of 2023 Annual General MeetingMay 23, 2023 | proactiveinvestors.comCardiol Therapeutics earns higher price target from broker as it ends 1Q with sufficient cash to advance CardiolRx candidateApril 28, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc down on Thursday (CRDL)April 19, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc up on Wednesday (CRDL)April 19, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc down on Tuesday (CRDL)April 14, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc down on Friday (CRDL)April 11, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc up on Monday (CRDL)March 29, 2023 | proactiveinvestors.comCardiol Therapeutics offers an update on operations as it advances the development of its lead drug candidate CardiolRxMarch 29, 2023 | finance.yahoo.comCardiol Therapeutics Announces Year-End 2022 Update on OperationsMarch 7, 2023 | proactiveinvestors.comCardiol Therapeutics says new study results highlight the cardioprotective effects of cannabidiolJanuary 17, 2023 | finance.yahoo.comCardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for PericarditisJanuary 17, 2023 | proactiveinvestors.comCardiol Therapeutics enrolls first patient in Phase II CardiolRx study on recurrent pericarditisDecember 14, 2022 | proactiveinvestors.comCardiol Therapeutics commences Phase II study of CardiolRx for treatment of Recurrent PericarditisDecember 12, 2022 | proactiveinvestors.comCardiol Therapeutics kicks off a multi-center Phase II pilot study of CardiolRx for the treatment of recurrent pericarditisNovember 7, 2022 | proactiveinvestors.comCardiol Therapeutics unveils new study data highlighting protective effects of CardiolRx in acute pericarditisOctober 25, 2022 | seekingalpha.comCardiol to abandon COVID study of cannabis drug to focus on heart diseases trialsAugust 3, 2022 | finance.yahoo.comCardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. CRDL Media Mentions By Week CRDL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDL News Sentiment▼0.780.55▲Average Medical News Sentiment CRDL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDL Articles This Week▼90▲CRDL Articles Average Week Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MOLN News VXRT News DBVT News SCLX News CRDF News BCAB News VIGL News OMGA News LIFE News SGMO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDL) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
